HLS Therapeutics Past Earnings Performance
Past criteria checks 0/6
HLS Therapeutics's earnings have been declining at an average annual rate of -5.9%, while the Pharmaceuticals industry saw earnings growing at 1% annually. Revenues have been growing at an average rate of 2% per year.
Key information
-5.9%
Earnings growth rate
-1.9%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | 2.0% |
| Return on equity | -28.2% |
| Net Margin | -43.6% |
| Next Earnings Update | 09 May 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How HLS Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 63 | -28 | 28 | 0 |
| 30 Sep 23 | 63 | -29 | 30 | 0 |
| 30 Jun 23 | 63 | -26 | 30 | 0 |
| 31 Mar 23 | 62 | -26 | 30 | 0 |
| 31 Dec 22 | 61 | -24 | 30 | 0 |
| 30 Sep 22 | 61 | -21 | 29 | 0 |
| 30 Jun 22 | 61 | -19 | 28 | 0 |
| 31 Mar 22 | 60 | -12 | 25 | 0 |
| 31 Dec 21 | 60 | -13 | 26 | 0 |
| 30 Sep 21 | 61 | -16 | 27 | 0 |
| 30 Jun 21 | 59 | -16 | 27 | 0 |
| 31 Mar 21 | 57 | -20 | 28 | 0 |
| 31 Dec 20 | 56 | -15 | 26 | 0 |
| 30 Sep 20 | 54 | -20 | 25 | 0 |
| 30 Jun 20 | 54 | -21 | 23 | 0 |
| 31 Mar 20 | 55 | -16 | 21 | 0 |
| 31 Dec 19 | 54 | -20 | 19 | 0 |
| 30 Sep 19 | 57 | -7 | 17 | 0 |
| 30 Jun 19 | 59 | -25 | 16 | 0 |
| 31 Mar 19 | 61 | -24 | 15 | 0 |
| 31 Dec 18 | 61 | -25 | 14 | 0 |
| 30 Sep 18 | 65 | -26 | 13 | 0 |
| 30 Jun 18 | 70 | -8 | 13 | 0 |
| 31 Mar 18 | 73 | -8 | 12 | 0 |
| 31 Dec 17 | 75 | -6 | 12 | 0 |
| 30 Sep 17 | 71 | -11 | 11 | 0 |
| 31 Dec 16 | 54 | -15 | 10 | 0 |
| 31 Dec 15 | 20 | -10 | 9 | 0 |
Quality Earnings: HLTR.F is currently unprofitable.
Growing Profit Margin: HLTR.F is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: HLTR.F is unprofitable, and losses have increased over the past 5 years at a rate of 5.9% per year.
Accelerating Growth: Unable to compare HLTR.F's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: HLTR.F is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-13.2%).
Return on Equity
High ROE: HLTR.F has a negative Return on Equity (-28.18%), as it is currently unprofitable.